Survival of breast cancer patients with meningeal carcinomatosis.
BACKGROUND
Breast cancer is the leading nonhematologic cause of meningeal carcinomatosis (MC). The aim of this study was to report the outcome of patients diagnosed with breast cancer MC and treated in single institution by a high-dose intrathecal methotrexate (MTX) regimen.


METHODS
Ninety-one patients were diagnosed with breast cancer MC from 2000 to 2007. Intrathecal treatment was MTX 15 mg/day (days 1-5), hydrocortisone acetate (day 1) and oral folinic acid (days 1-5), repeated every 2 weeks. Patients and tumor characteristics were associated with the early clinical and biological outcome and with the overall survival (OS).


RESULTS
The median survival was 4.5 months (range 0-53). In multivariate analysis, adverse prognostic factors at diagnosis were performance status >2 [P = 0.006, response rate (RR) = 0.33 (0.15-0.71)], more than three chemotherapy regimens before MC diagnosis [P = 0.03, RR = 0.40 (0.19-0.93)], negative hormone receptor status [P = 0.02, RR = 0.4 (0.19-0.90)] and high Cyfra 21-1 level [P = 0.048, RR = (0.09-0.99)]. Clinical progression after one cycle and biological response after two cycles were independently associated with OS [P < 0.001, RR = 0.09 (0.02-0.37) and P = 0.003, RR = 3.6 (1.5-8.5), respectively]. We propose a prognostic score in order to define three distinct groups of prognosis.


CONCLUSIONS
MC presents a poor prognosis, but 1-year survival rate was 25%. This score may become a useful tool for treatment decision and clinical trials.
Gauthier
H
H
Department of Medical Oncology, Institut Curie, Paris, France.
Guilhaume
M N
MN
Department of Medical Oncology, Institut Curie, Paris, France.
Bidard
F C
FC
Department of Medical Oncology, Institut Curie, Paris, France.
Pierga
J Y
JY
Department of Medical Oncology, Institut Curie, Paris, France; University Paris Descartes, Paris.
Girre
V
V
Department of Medical Oncology, Institut Curie, Paris, France.
Cottu
P H
PH
Department of Medical Oncology, Institut Curie, Paris, France.
Laurence
V
V
Department of Medical Oncology, Institut Curie, Paris, France.
Livartowski
A
A
Department of Medical Oncology, Institut Curie, Paris, France.
Mignot
L
L
Department of Medical Oncology, Institut Curie, Paris, France.
Diéras
V
V
Department of Medical Oncology, Institut Curie, Paris, France. Electronic address: veronique.dieras@curie.net.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D018270:Carcinoma, Ductal, Breast / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D018275:Carcinoma, Lobular / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D002955:Leucovorin / Q000627:therapeutic use; D055756:Meningeal Carcinomatosis / Q000188:drug therapy / Q000209:etiology*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D014803:Vitamin B Complex / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000964:Antimetabolites, Antineoplastic; D014803:Vitamin B Complex; D002955:Leucovorin; D006854:Hydrocortisone; D008727:Methotrexate